Trials / Completed
CompletedNCT04577742
Uveal Melanoma and Brachytheraphy: Long-term Outcomes.
Long-term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 350 (actual)
- Sponsor
- Federico II University · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- —
Summary
This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | 106 Ruthenium plaque brachytherapy | All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2020-03-20
- Completion
- 2020-03-30
- First posted
- 2020-10-08
- Last updated
- 2020-10-08
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04577742. Inclusion in this directory is not an endorsement.